False-positive rifampicin resistance on Xpert®MTB/RIF caused by a silent mutation in the rpoB gene

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 10, 2014, Pages 1255-1257

  Mathys, V ^a   Van De Vyvere, M ^b   De Droogh, E ^c   Soetaert, K ^a   Groenen, G ^d  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b ZiekenhuisNetwerk Antwerpen   (Belgium)

^c ZNA Middelheim ^*  (Belgium)

^d Belgian Lung and Tuberculosis Association   (Belgium)

Author keywords

Gene sequencing; Molecular test; Tuberculosis

Indexed keywords

AMIKACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; BACTERIAL PROTEIN; QUINOLONE DERIVATIVE; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC KIT; DNA SEQUENCE; FALSE POSITIVE RESULT; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG INFILTRATE; LUNG TUBERCULOSIS; MALE; MICROSCOPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RPOB GENE; SPUTUM ANALYSIS; XPERT MTB RIF ASSAY; AMINO ACID SEQUENCE; DRUG EFFECTS; GENETICS; GENOTYPE; MICROBIOLOGY; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATION; PHENOTYPE; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, PULMONARY;

AGED; AMIKACIN; AMINO ACID SEQUENCE; ANTIBIOTICS, ANTITUBERCULAR; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; ETHIONAMIDE; FLUOROQUINOLONES; GENOTYPE; HUMANS; ISONIAZID; MALE; MOLECULAR SEQUENCE DATA; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PYRAZINAMIDE; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84907185217     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0297     Document Type: Article

References (10)

1. World Health Organization Policy statement: automated realtime nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RMP system WHO/HTM/TB/2011.4 Geneva, Switzerland: WHO, 2011.
2. Van Deun A, Aung K J, Bola V, et al Rifampin drug resistance tests for tuberculosis: challenging the gold standard J Clin Microbiol 2013; 51: 2633-2640.
3. World Health Organ ization Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RMP system for the diagnosis of pulmonary and extrapulmonary TB in adults and children: polic y update WHO/HTM/TB/2013.14 Geneva, Switzerland: WHO, 2013.
4. Williamson D A, Roberts S A, Bower J E, et al Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant My cobacterium tuberculosis Int J Tuberc Lung Dis 2012; 16: 216-220.
5. Ho J, Jelfs P, Sintchencko V.Phenotypically occult multidrugresistant Mycobacterium tuberculosis: dilemmas in diagnosis and trea tment J Antimicrob Chemother 2013; 68: 2915-2920.
6. Rigouts L, Gumusboga M, de Rijk W B, et al Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isol ates with specific rpoB mutations J Clin Microbiol 2013; 51: 2641-2645.
7. Van Deun A, Barrera L, Bastian I, et al Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results J Clin Microbiol 2009; 47: 3501-3506.
8. Alonso M, Palacios J J, Herranz M, et al Isolation of Mycobacterium tuberculosis strains with a silent mutation in rpoB leading to potential misassignment of resistance category J Clin Microbiol 2011; 49: 2688-2690 .
9. Williamson D A, Basu I, Bower J, Freeman J T, Henderson G, Roberts S A.An evaluation of the Xpert MTB/RMP assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis Diagn Microbio l Infect Dis 2012; 74: 207-209.
10. Association of Public Health Laboratories Fact sheet: laboratory considerations for use of Cepheid Xpertw MTB/RMP assay Silver Spring, MD, USA: APHL, 2013.